Dr. Jasmine Luzum (formerly Talameh), PharmD, PhD, BCPS joined the Department of Clinical Pharmacy in July 2016. She received her PharmD summa cum laude from the University of Pittsburgh in 2008 and her PhD in Pharmaceutical Sciences from the University of North Carolina at Chapel Hill Eshelman School of Pharmacy in 2013. She completed a Post-Doctoral Fellowship at the Ohio State University College of Medicine and Center for Pharmacogenomics in 2016. She became a Board-Certified Pharmacotherapy Specialist by the Board of Pharmacy Specialties in 2015 and an Applied Pharmacologist by the American Board of Clinical Pharmacology in 2015.
Dr. Luzum runs a clinical and translational research lab focused on cardiovascular precision medicine. You can check out her lab website here. The long-term goal of Dr. Luzum’s research is to improve cardiovascular medication outcomes with precision medicine. She is especially interested in differences in cardiovascular drug response by race and genomics. Her lab uses a variety of research approaches, including genetics/genomics, electronic health records, and bioinformatics. Her research has been funded by the most prestigious sponsors (e.g., NIH, American Heart Association, and American Foundation for Pharmaceutical Education), published in top journals (e.g., Cell Metabolism, Clinical Pharmacology & Therapeutics, Journal of the American Heart Association), and presented at major conferences (e.g., American College of Cardiology Scientific Sessions and the NIH Pharmacogenomics Research Network).
Michael Kenes received his Doctor of Pharmacy from the University of Illinois Chicago and completed his Pharmacy Practice Residency at the Cleveland Clinic and his Critical Care Pharmacy Residency at Vanderbilt University Medical Center. Dr. Kenes has also served as a Clinical Pharmacy Specialist in the medical intensive care unit at Wake Forest Baptist Health prior to joining our College. His clinical practice site is the critical care medicine unit at Michigan Medicine.
Since his start date in February of this year, he has led clinical pharmacy services in the newly opened (and since closed!) 50-bed RICU or COVID ICU at Michigan Medicine. He helped to streamline and standardized care for these challenging patients and educate the many volunteer providers that rotated through the unit. He has led or assisted in several ongoing research projects including:
Comparing the effect of propofol on development of hypertriglyceridemia in patients with COVID vs. non-COVID associated ARDS
Examining the effect of tracheostomy on sedation reduction in mechanically ventilated COVID ICU patients
Characterizing the prevalence and risk factors for delirium in COVID ICU patients
Utilization of neuromuscular blockade in COVID vs. non-COVID associated ARDS
Michael looks forward to returning to the critical care medicine unit to further establish his practice and educate our student and resident learners.